{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:27:58Z","timestamp":1721176078793},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,15]]},"DOI":"10.7759\/cureus.64621","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T05:20:36Z","timestamp":1721107236000},"source":"Crossref","is-referenced-by-count":0,"title":["A Patient With Hepatocellular Carcinoma and Lung Metastasis Successfully Underwent Curative Surgery Following the Downstaging Treatment: A Case Report"],"prefix":"10.7759","author":[{"given":"Shiguo","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risheng","family":"Que","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9549-7","article-title":"Salvage surgery following downstaging of unresectable hepatocellular carcinoma - a strategy to increase resectability","volume":"14","author":"Lau WY","year":"2007","unstructured":"Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma - a strategy to increase resectability. Ann Surg Oncol. 2007, 14:3301-9. 10.1245\/s10434-007-9549-7","journal-title":"Ann Surg Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-020-00497-7","article-title":"Why adjuvant and neoadjuvant therapy failed in HCC. Can the new immunotherapy be expected to be better?","volume":"51","author":"Dikilitas M","year":"2020","unstructured":"Dikilitas M. Why adjuvant and neoadjuvant therapy failed in HCC. Can the new immunotherapy be expected to be better?. J Gastrointest Cancer. 2020, 51:1193-6. 10.1007\/s12029-020-00497-7","journal-title":"J Gastrointest Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11535-5","article-title":"Efficacy and safety analysis of TACE\u2009+\u2009donafenib\u2009+\u2009toripalimab versus TACE\u2009+\u2009sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study","volume":"23","author":"Lu H","year":"2023","unstructured":"Lu H, Liang B, Xia X, Zheng C. Efficacy and safety analysis of TACE\u2009+\u2009donafenib\u2009+\u2009toripalimab versus TACE\u2009+\u2009sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study. BMC Cancer. 2023, 23:1033. 10.1186\/s12885-023-11535-5","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2023.59.2.3507751","article-title":"Donafenib in hepatocellular carcinoma","volume":"59","author":"Chen R","year":"2023","unstructured":"Chen R, Ielasi L, di Carlo A, Tovoli F. Donafenib in hepatocellular carcinoma. Drugs Today (Barc). 2023, 59:83-90. 10.1358\/dot.2023.59.2.3507751","journal-title":"Drugs Today (Barc)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin S","year":"2021","unstructured":"Qin S, Bi F, Gu S, et al.. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol. 2021, 39:3002-11. 10.1200\/JCO.21.00163","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783236","article-title":"Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma","volume":"12","author":"Xing R","year":"2021","unstructured":"Xing R, Gao J, Cui Q, Wang Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021, 12:783236. 10.3389\/fimmu.2021.783236","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03060-w","article-title":"Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice","volume":"71","author":"Chen K","year":"2022","unstructured":"Chen K, Wei W, Liu L, et al.. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunol Immunother. 2022, 71:1063-74. 10.1007\/s00262-021-03060-w","journal-title":"Cancer Immunol Immunother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2242384","article-title":"Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials","volume":"55","author":"Zhang YL","year":"2023","unstructured":"Zhang YL, Cui XJ, Xing H, Ning HF, Dong P, Wang GZ. Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials. Ann Med. 2023, 55:2242384. 10.1080\/07853890.2023.2242384","journal-title":"Ann Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0794-6","article-title":"Emerging agents and regimens for hepatocellular carcinoma","volume":"12","author":"Zhu XD","year":"2019","unstructured":"Zhu XD, Sun HC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 2019, 12:110. 10.1186\/s13045-019-0794-6","journal-title":"J Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4157","article-title":"Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy","volume":"37","author":"Kelley RK","year":"2019","unstructured":"Kelley RK, Cheng AL, Braiteh FS, et al.. Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. J Clin Oncol. 2019, 37:4157.","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel TJ","year":"2003","unstructured":"Curiel TJ, Wei S, Dong H, et al.. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003, 9:562-7. 10.1038\/nm863","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1385\/IR:23:2-3:263","article-title":"VEGF as a mediator of tumor-associated immunodeficiency","volume":"23","author":"Ohm JE","year":"2001","unstructured":"Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001, 23:263-72. 10.1385\/IR:23:2-3:263","journal-title":"Immunol Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0409","article-title":"Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses","volume":"13","author":"Fricke I","year":"2007","unstructured":"Fricke I, Mirza N, Dupont J, et al.. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007, 13:4840-8. 10.1158\/1078-0432.CCR-07-0409","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan KA","year":"2018","unstructured":"Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018, 15:310-24. 10.1038\/nrclinonc.2018.9","journal-title":"Nat Rev Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/path.4340","article-title":"IFN\u03b3-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4","volume":"233","author":"Deng J","year":"2014","unstructured":"Deng J, Liu X, Rong L, et al.. IFN\u03b3-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4. J Pathol. 2014, 233:170-82. 10.1002\/path.4340","journal-title":"J Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901073","article-title":"Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis","volume":"183","author":"Lu Y","year":"2009","unstructured":"Lu Y, Yang W, Qin C, Zhang L, Deng J, Liu S, Qin Z. Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol. 2009, 183:6413-21. 10.4049\/jimmunol.0901073","journal-title":"J Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/269948-a-patient-with-hepatocellular-carcinoma-and-lung-metastasis-successfully-underwent-curative-surgery-following-the-downstaging-treatment-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T05:20:40Z","timestamp":1721107240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/269948-a-patient-with-hepatocellular-carcinoma-and-lung-metastasis-successfully-underwent-curative-surgery-following-the-downstaging-treatment-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.64621","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}